VC
VERA icon

Vivo Capital’s Vera Therapeutics VERA Stock Holding History

Vivo Capital’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-400,666
Closed -$7.75M – 49
2022
Q4 		$7.75M Sell
400,666
-266,000
-40% -$4.82M 0.89% 25
2022
Q3 		$14.2M Hold
666,666
– – 1.57% 19
2022
Q2 		$9.07M Hold
666,666
– – 0.91% 27
2022
Q1 		$15.7M Buy
+666,666
New +$14.3M 1.08% 21

Other funds holding VERA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital's VERA Position: Q1 2023 in Review

Vivo Capital sold out of Vera Therapeutics (VERA) in Q1 2023, closing a stake of 400,666 shares — an estimated $7.75M sold.

Vivo Capital first reported a position in VERA in Q1 2022 and held it in 4 quarters. The position peaked at $15.7M in Q1 2022. 70 funds tracked by Wall St. Rank hold VERA as of Q1 2023.

  • Vivo Capital reported no remaining Vera Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Vivo Capital sold 400,666 Vera Therapeutics shares in Q1 2023, an estimated $7.75M.
  • Vivo Capital first reported a position in Vera Therapeutics in Q1 2022 and held it in 4 quarters.
  • Vivo Capital's Vera Therapeutics position peaked at $15.7M in Q1 2022.
  • 70 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2023.

Based on Vivo Capital's 13F filing for Q1 2023, filed 15 May 2023.